By David Cassak
For most medical device start-ups, a successful entrée into the marketplace rests on making their technology a little bit better—a...
Welcome to In Vivo
Create an account to read this article
Already a subscriber?
Cameron Health and the Revolution From Below
The ICD market in cardiac rhythm management has been one of the medical device industry's fastest growing markets over the past several years. Yet for all its success, only about 20% of the patients who could benefit from an ICD get one. Why is that? Officials from Cameron Health argue that the complexity of current devices frustrate many cardiologists and force them to hand patients over to electrophysiologists, a move that they often resist. Now, Cameron hopes to blow open the untapped portion of the market with a device that is simpler to use, one that cardiologists will feel comfortable implanting.
More from Innovation
• By
With drug pricing policies potentially squeezing industry margins, companies are increasingly turning to AI-driven trial optimization to rescue sub-optimal studies and accelerate development timelines.
The biotech's C1q inhibitor, vonaprument, preserved vision but missed the primary Phase II endpoint on lesion growth. The stakes are high for a Phase III with a different primary endpoint.
• By
The mathematician-turned-CEO is building an atlas of clinical immune biology to revolutionize precision medicine.
• By
Three digital twin approaches compete: image-based precision, phenotypic modeling and massive data aggregation.
More from In Vivo
The biotech's C1q inhibitor, vonaprument, preserved vision but missed the primary Phase II endpoint on lesion growth. The stakes are high for a Phase III with a different primary endpoint.
An interactive look at pharma, medtech and diagnostics deals made during August 2025. Data courtesy of Biomedtracker.
• By
The mathematician-turned-CEO is building an atlas of clinical immune biology to revolutionize precision medicine.